Beyond BRCA

Markers beyond BRCA to identify patients who could benefit from PARP inhibitors

Researchers at the German Cancer Research Center have identified synthetic lethal markers beyond BRCA that expand the pool of patients who may benefit from PARP inhibitors and other compounds targeting DNA damage repair pathways.

In a paper published in Nature Communications this

Read the full 413 word article

How to gain access

Continue reading with a
two-week free trial.